

---

Subject: Eirion Therapeutics

Posted by [Jim](#) on Tue, 16 Mar 2021 07:12:38 GMT

[View Forum Message](#) <> [Reply to Message](#)

---

In den USA hat das Unternehmen Eirion Therapeutics eine Pressemitteilung zu ihrem Wirkstoff ET-02 herausgegeben.

"Controlled non-clinical studies of human scalp tissue affected by androgenic alopecia, ET-02 demonstrated approximately twice the hair growth compared to a control treatment over approximately 4 months, which was statistically significant, and amounted to approximately three times the hair growth per centimeter over that which was observed in minoxidil clinical trials that were 12 months in duration."

<https://practicaldermatology.com/news/eirion-therapeutics-closes-40m-series-a-investment-and-licensing-deal-with-shanghai-haohai-biological-technology>

---